Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Emend To Be Covered Under Part B In Draft CMS Coverage Decision

This article was originally published in The Pink Sheet Daily

Executive Summary

The anti-emetic would be covered by Medicare Part B when used in combination with a 5-HT3 antagonist and dexamethasone in patients refractory to standard treatments, CMS says. Other uses of Emend would be covered under Part D beginning in 2006.
Advertisement

Related Content

Merck's Emend Granted Broad Coverage Under Medicare Part B
Merck's Emend Granted Broad Coverage Under Medicare Part B
MedPAC To Examine Hospitals’ Handling Costs For Outpatient Drugs
MedPAC To Examine Hospitals’ Handling Costs For Outpatient Drugs
Merck Emend Medicare National Coverage Decision Expected By April 2005
Merck Emend Medicare National Coverage Decision Expected By April 2005

Topics

Advertisement
UsernamePublicRestriction

Register

PS061065

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel